导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -19.42% | 4358/4773 |
| 近一周 | -4.12% | 5014/5465 |
| 近一月 | -6.00% | 3991/5421 |
| 近一季 | -3.15% | 1560/5231 |
| 近半年 | -22.20% | 4521/4920 |
| 近一年 | -24.07% | 4070/4394 |
| 近两年 | 35.09% | 2099/2954 |
| 近三年 | 5.06% | 1841/2253 |
| 成立以来 | 2.34% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.74% 2889/4961 |
-16.27% 4725/5312 |
- - |
- - |
| 2025 | 26.91% 1590/4813 |
5.23% 805/3635 |
4.99% 667/4076 |
22.05% 1705/4524 |
-5.89% 3640/4813 |
| 2024 | 6.68% 1734/3463 |
2.17% 809/2808 |
-16.28% 2727/3014 |
20.07% 766/3129 |
3.88% 758/3463 |
| 2023 | 20.43% 20/2656 |
38.96% 32/2280 |
6.02% 51/2385 |
-13.17% 2139/2515 |
-5.85% 1530/2655 |
| 2022 | -28.52% 1566/2207 |
-21.04% 1596/1919 |
-3.39% 1816/2016 |
-17.00% 1538/2113 |
12.88% 116/2208 |
| 2021 | -0.37% 750/1822 |
-8.07% 1075/1255 |
1.55% 1045/1330 |
-12.33% 1303/1466 |
21.72% 21/1822 |
| 2020 | 2.16% 924/1250 |
-5.76% 435/1028 |
18.66% 329/1067 |
1.19% 1030/1164 |
-9.71% 1163/1184 |
| 2019 | 27.34% 548/1092 |
31.48% 200/739 |
-15.48% 784/788 |
3.66% 243/850 |
10.55% 121/918 |
| 2018 | - - |
- - |
-17.33% 573/631 |
-12.52% 614/660 |
-7.57% 69/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 广发中证传媒ETF联接C VS. 长安沪深300非周期A(740101) |